Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Evaxion Biotech ( (EVAX) ).
On June 25, 2025, Evaxion A/S announced the expansion of its R&D pipeline with a new vaccine program targeting Group A Streptococcus (GAS), named EVX-B4. This initiative underscores the significant medical and commercial potential of addressing GAS, which causes numerous infections globally. The addition of EVX-B4 aligns with Evaxion’s strategy to enhance its pipeline, supporting its partnership goals and increasing the number of assets for out-licensing.
The most recent analyst rating on (EVAX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by its strong revenue growth and positive earnings call, highlighting R&D progress and strategic partnerships. However, financial instability and negative profitability weigh heavily on the score, alongside a challenging valuation position.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a clinical-stage TechBio company specializing in developing vaccines powered by its AI-Immunology™ platform. The company focuses on creating novel immunotherapies for cancer, bacterial diseases, and viral infections, aiming to transform patient lives through innovative and targeted treatment options.
Average Trading Volume: 96,578
Technical Sentiment Signal: Sell
Current Market Cap: $3.42M
See more data about EVAX stock on TipRanks’ Stock Analysis page.